Article Text

Download PDFPDF
Drug information (i. Anti-infectives, ii. cytostatics, iii. others)
The use of intravenous linezolid†
  1. M.C. Sánchez-Mulero,
  2. B. Arribas-Diaz,
  3. M.P. Molina-Guillen,
  4. I. Sanchez-Quiles,
  5. M.D. Nájera-Perez,
  6. A. Boso-Ribelles,
  7. J.C. Titos-Arcos,
  8. A. Moregó-Soler,
  9. M.M. Sanchez-Catalicio,
  10. J. Pastor-Cano
  1. 1Hospital Morales Meseguer, Pharmacy, Murcia, Spain


Background Linezolid is an antibiotic approved for treatment of nosocomial pneumonia (NP), community-acquired pneumonia (CAP) and complicated skin and soft tissue infections caused by Gram-positive bacteria susceptible to linezolid.

Purpose To determine the use of intravenous linezolid in a 400-bed general hospital, where its use is only sanctioned for:

  • NP due to methicillin-sensitive and methicillin-resistant S. aureus (MSSA and MRSA) or methicillin-sensitive S. pneumoniae.

  • CAP due to methicillin-sensitive S. pneumoniae or MSSA.

  • Skin and soft tissue infections with MSSA or MRSA, S. pyogenes or S. agalactiae.

Materials and methods One-year retrospective study (2010). Data were obtained from: clinical records, Savac and Selene programs and laboratory tests. The case report form used had the following items: diagnoses, bacterial culture, indication, dose, duration, concomitant antibacterial treatment, previous treatment with glycopeptides and adverse effects, creatinine level and possibility of oral administration.

Results Sixty-seven episodes corresponding to 52 patients whose mean age was 60.7 years. Episodes were reviewed from: intensive medicine (68.3%), surgery (15%), internal medicine (6.6%), other (10.1%). Only 17.3% of patients used the drug according to indications for which it is restricted according to the hospital protocol. Non-indicated uses included: pneumonia not matching the above conditions (20.3%) and postoperative abdominal abscess (20.3%). In 100% of cases bacterial culture was performed, and its use was justified in 19% of cases. The recommended dose was used in 95% of cases. Mean duration of therapy was 9.7 days. Significant concomitant antibiotics were: piperacillin-tazobactam (29.2%), meropenem (25.2%), cefepime (8%), and amikacin (8%). 41.6% had been treated previously with glycopeptides. Mean creatinine was 0.8 mg/dL.

Conclusions There is low compliance with the authorised indications. Those treated the longest (11.5%) had blood toxicity. Almost half could have been treated orally at the same dose (100% bioavailability).

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.